Clearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
November 24, 2021
Ryan Allway November 24th, 2021 Psychedelics Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on... Read more
Ryan Allway May 3rd, 2021 Psychedelics San Diego, California–(Newsfile Corp. – May 3, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”) a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Fluence to provide design and training for the... Read more
